Alator Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $4.2M

Overview

Alator Biosciences is a US-based, privately-held supplier of research products and custom manufacturing services, operating since 2016. The company positions itself as a value-driven partner, sourcing high-quality products from manufacturers to offer competitive pricing and hands-on service to the biotech and academic research sectors. Its business model is purely service-based, acting as a distributor and contract manufacturer rather than developing its own therapeutic pipeline.

OncologyAntibodies

Technology Platform

Partnership-based distribution and custom manufacturing model for research enzymes, reagents, and biochemicals.

Funding History

1

Total raised:$4.2M

Seed$4.2MUndisclosedNov 15, 2022

Opportunities

The company can capitalize on the persistent demand for core research tools and the need for flexible, small-to-mid-scale custom manufacturing services within the growing life sciences R&D sector.

Building a reputation for reliability and value can help it capture market share from larger, less agile competitors.

Risk Factors

Alator faces intense competition from large global distributors and relies on third-party manufacturers for its product supply, creating vulnerability.

Its service-based model with no proprietary IP makes differentiation challenging and exposes it to margin pressure and client attrition.

Competitive Landscape

Alator competes in the highly fragmented life science research tools market, facing giants like Thermo Fisher and Merck as well as numerous small distributors. Its competitive edge is purportedly based on a combination of quality, price, and personalized service, rather than unique products.

More companies in Biologics / Biosimilars →More companies in United States →